摘要:
The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 53070, 15985, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-53070, 15985, 26583, 21953, m32404, 14089, or 23436 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要:
The invention provides isolated nucleic acids molecules, designated 26443 and 46873 nucleic acid molecules, which encode novel human hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26443 and 46873 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26443 and 46873 gene has been introduced or disrupted. The invention still further provides isolated 26443 and 46873 proteins, fusion proteins, antigenic peptides and anti-26443 or 46873 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要:
The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.
摘要:
The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要:
The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875,46842,33201, 83378,84233,64708, 85041,84234,21617, 55562,23566,33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要:
The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
摘要:
The invention provides isolated nucleic acids molecules, designated 14815 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14815 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14815 gene has been introduced or disrupted. The invention still further provides isolated 14815 proteins, fusion proteins, antigenic peptides and anti-14815 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要:
The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要:
Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets.
摘要:
The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.